fn1

NCGC00378430 is a potent SIX1/EYA2 interaction inhibitor that disrupts the [SIX1/EYA2] complex, EMT, and metastasis.

Pfn1-IN-C1, an inhibitor of Profilin1 (Pfn1), has been shown to reduce the overall level of cellular filamentous (F)-actin, slow EC migration and proliferation, and inhibit the angiogenic ability of EC both in vitro and ex vivo.

Pfn1-IN-C2, an inhibitor of Profilin1 (Pfn1), has been shown to reduce the overall level of cellular filamentous (F)-actin, slow EC migration and proliferation, and inhibit the angiogenic ability of EC both in vitro and ex vivo.

FN-1501-propionic acid, a CDK2/9 ligand, in conjunction with a CRBN ligand, has been utilized in the design of a PROTAC CDK2/9 degrader.

Afabicin is an antibiotic targeting Staphylococcus aureus, exhibiting highly effective inhibitory activity against both susceptible and methicillin-resistant (MRSA) S. aureus strains. It is used to treat acute bacterial skin and skin structure infections. Afabicin is the prodrug of Debio1452.

FN-1501 is a potent FLT3 and CDK inhibitor (IC50s: 2.47, 0.85, 1.96, and 0.28 nM for CDK2/cyclin A, CDK4/cyclin D1, CDK6/cyclin D1 and FLT3, respectively). FN-1501 also has anticancer activity.

FFN-102 (trifluoroacetate salt) is a synthetic biogenic neurotransmitter analog with pH-dependent fluorescence and electroactivity.

StA-IFN-1 is an inhibitor of the interferon (IFN) induction pathway with an IC50 value of 4.1 μM in a GFP reporter assay for IFN induction similar to TPCA-1 , which specifically inhibits the IKKβ component of the IFN induction pathway. It does not show inhibitory activity in a GFP reporter assay for IFN signaling in which ruxolitinib , which is specific for the IFN signaling component JAK1, is active. StA-IFN-1 reduces the levels of IFN-β, but not ISG MxA, mRNA, suggesting that it is selective for the IFN induction pathway and not the IFN signaling pathway.

AFN-1252 (Debio 1452)(Debio 1452) is an effective inhibitor of enoyl-acyl carrier protein reductase (FabI). It (≤0.12 μg/ml) inhibits all Clinicalal isolates of Staphylococcus aureus and Staphylococcus epidermidis.

AFN-1252 tosylate is an enoyl-ACP Reductase inhibitor.

SC 53606 is a potent and selective antagonist of 5-hydroxytryptamine4 receptor.

AMPCP is an Ecto-5'-nucleotidase (CD73) inhibitor.

AFN-1252, also known as AFN-12520000; API-1252; Debio-1452, is FASII Inhibitor which is potentially for the treatment of acute bacterial skin. AFN-1252 exhibits typical MIC(90) values of ≤0·015 μg/ml against diverse clinical isolates of S. aureus, oral absorption, long elimination half-live and efficacy in animal models. AFN-1252 efficiently blocked daptomycin-induced phospholipid decoy production, even in the case of isolates resistant to AFN-1252, which prevented the inactivation of daptomycin and resulted in sustained bacterial killing. In turn, daptomycin prevented the fatty acid-dependent emergence of AFN-1252-resistant isolates in vitr

Aurintricarboxylic acid (NSC-4056) is a strong inhibitor of topoisomerases and other nucleases. It is a potent inhibitor of ribonuclease and topoisomerase II by preventing the binding of the nucleic acid to the enzyme.

L524-0366 ([1-(3-chlorophenyl)triazol-4-yl]-thiomorpholino-methanone) is a TWEAK-Fn14 signaling cascade inhibitor.

BAY 2666605 is an orally active inhibitor of PDE3A (IC50 = 87 nM) and PDE3B (IC50 = 50 nM) with noted anticancer effects.

GED-0507-34 Levo ((S)-3-(4-Aminophenyl)-2-methoxypropanoic acid), an orally available PPARγ modulator for amelioration of inflammation-driven intestinal fibrosis, decreased the expression of the pro-fibrotic genes Acta2, COL1a1, and Fn1, reduced the protein levels of α-SMA and collagen I-II, the main markers of fibrosis, as well as the major components of the TGFβ/Smad pathway, and decreased the expression of IL-13, CTGF, TGFB and ACTA1, and inhibited TGF-β-induced activation of fibroblasts and IECs cell lines.

Micvotabart is a humanized IgG1κ monoclonal antibody targeting FN1, with HumanIgG1kappa, Isotype Control serving as its corresponding isotype control.